Prevalence of Lynch syndrome among patients with newly diagnosed endometrial cancers

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Egoavil, Cecilia ^a   Alenda, Cristina ^a   Castillejo, Adela ^b   Paya, Artemio ^a   Peiro, Gloria ^a   Sánchez Heras, Ana Beatriz ^b   Castillejo, Maria Isabel ^b   Rojas, Estefania ^a   Barberá, Victor Manuel ^b   Cigüenza, Sonia ^a   Lopez, Jose Antonio ^a   Piñero, Oscar ^a   Román, Maria Jose ^a   Martínez Escoriza, Juan Carlos ^a   Guarinos, Carla ^a   Perez Carbonell, Lucia ^a   Aranda, Francisco Ignacio ^a   Soto, Jose Luis ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b Elche University Hospital   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; MLH1 PROTEIN, HUMAN; NUCLEAR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ADULT; AGE; AGED; ARTICLE; CANCER SCREENING; DNA METHYLATION; ENDOMETRIUM CANCER; FEMALE; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MLH1 GENE; PREVALENCE; SPAIN; CANCER GRADING; CANCER STAGING; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; COMPLICATION; ENDOMETRIAL NEOPLASMS; GENETICS; GERMLINE MUTATION; MIDDLE AGED; VERY ELDERLY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA METHYLATION; DNA MISMATCH REPAIR; ENDOMETRIAL NEOPLASMS; FEMALE; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NUCLEAR PROTEINS; PREVALENCE;

EID: 84892406685     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079737     Document Type: Article

References (44)

1. Folkins AK, Longacre TA (2013) Hereditary gynaecological malignancies: advances in screening and treatment. Histopathology 62: 2-30. doi:10.1111/his.12028. PubMed: 23240667.
2. Ferlay J, Parkin DM, Steliarova-Foucher E (2013) Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 49: 1374-1403. doi:10.1016/j.ejca.2012.12.027. PubMed: 23485231.
3. Gruber SB, Thompson WD (1996) A population-based study of endometrial cancer and familial risk in younger women. Cancer and Steroid Hormone Study Group. Cancer Epidemiol Biomarkers Prev 5: 411-417.
4. Peltomäki P (2003) Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 21: 1174-1179. doi: 10.1200/JCO.2003.04.060. PubMed: 12637487.
5. Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. N Engl J Med 348: 919-932. doi:10.1056/NEJMra012242. PubMed: 12621137.
6. Barrow E, Hill J, Evans DG (2013) Cancer risk in Lynch Syndrome. Fam Cancer 12: 229-240. doi:10.1007/s10689-013-9615-1. PubMed: 23604856.
7. Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A et al. (2013) (2013) Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 62: 812-823. doi:10.1136/gutjnl-2012-304356. PubMed: 23408351.
8. Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A et al. (1998) Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 338: 1481-1487. doi:10.1056/NEJM199805213382101. PubMed: 9593786.
9. Salovaara R, Loukola A, Kristo P, Kääriäinen H, Ahtola H et al. (2000) Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 18: 2193-2200. PubMed: 10829038.
10. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K et al. (2005) Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352: 1851-1860. doi:10.1056/NEJMoa043146. PubMed: 15872200.
11. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K et al. (2008) Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 26: 5783-5788. doi:10.1200/JCO.2008.17.5950. PubMed: 18809606.
12. Pérez-Carbonell L, Ruiz-Ponte C, Guarinos C, Alenda C, Payá A et al. (2012) Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Gut 61: 865-872. doi:10.1136/gutjnl-2011- 300041. PubMed: 21868491.
13. Hampel H, Frankel W, Panescu J, Lockman J, Sotamaa K et al. (2006) Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 66: 7810-7817. doi:10.1158/0008-5472. CAN-06-1114. PubMed: 16885385.
14. Hampel H, Panescu J, Lockman J, Sotamaa K, Fix D et al. (2007) Comment on: Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients. Cancer Res 67: 9603. doi:10.1158/0008-5472. CAN-07-2308. PubMed: 17909073.
15. Moline J, Mahdi H, Yang B, Biscotti C, Roma AA et al. (2013) Implementation of Tumor Testing for Lynch Syndrome in Endometrial Cancers at a Large Academic Medical Center. Gynecol Oncol 130: 121-126. doi:10.1016/j.ygyno. 2013.04.022. PubMed: 23612316.
16. Silverberg SG, Kurman RJ, Nogales F (2003) Tumours of the uterine corpus. In: FA TavassoliP Devilee. Pathology and genetics of tumours of the breast and female genital organs. Lyon. IARC Press. pp. 217-228.
17. Peiró G, Peiró FM, Ortiz-Martínez F, Planelles M, Sánchez-Tejada L et al. (2013) Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment. Hum Pathol 44: 218-225. doi:10.1016/j.humpath.2012. 05.008. PubMed: 22955108.
18. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A et al. (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96: 261-268. doi:10.1093/jnci/djh034. PubMed: 14970275.
19. Jover R, Payá A, Alenda C, Poveda MJ, Peiró G et al. (2004) Defective mismatch-repair colorectal cancer: clinicopathologic characteristics and usefulness of immunohistochemical analysis for diagnosis. Am J Clin Pathol 122: 389-394. doi:10.1309/V9PGK2Y260VFVULR. PubMed: 15362369.
20. Suraweera N, Duval A, Reperant M, Vaury C, Furlan D et al. (2002) Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 123: 1804-1811. doi:10.1053/gast.2002.37070. PubMed: 12454837.
21. Deng G, Chen A, Hong J, Chae HS, Kim YS (1999) Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res 59: 2029-2033. PubMed: 10232580.
22. Pérez-Carbonell L, Alenda C, Payá A, Castillejo A, Barberá VM et al. (2010) Methylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome. J Mol Diagn 12: 498-504. doi: 10.2353/jmoldx.2010.090212. PubMed: 20489114.
23. Richards CS, Bale S, Bellissimo DB, Das S, Grody WW et al. (2008) Molecular Subcommittee of the ACMG Laboratory Quality Assurance Committee. ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions2007. Genet Med 10: 294-300. doi:10.1097/GIM. 0b013e31816b5cae. PubMed: 18414213.
24. Ou J, Niessen RC, Vonk J, Westers H, Hofstra RM et al. (2008) A database to support the interpretation of human mismatch repair gene variants. Hum Mutat 29: 1337-1341. doi:10.1002/humu.20907. PubMed: 18951442.
25. Chongsuvivatwong Virasakdi (2012) epicalc: Epidemiological calculator. R package version 2.15.1.0. Retrieved onpublished at whilst December year 1111 from http://CRAN.R-project.org/package= epicalc.
26. Cook LS, Nelson HE, Stidley CA, Dong Y, Round PJ et al. (2013) Endometrial cancer and a family history of cancer. Gynecol Oncol 130: 334-339. doi:10.1016/j.ygyno.2013.04.053. PubMed: 23632205.
27. Shia J, Ellis NA, Paty PB, Nash GM, Qin J et al. (2003) Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colon cancer and sporadic colon cancer. Am J Surg Pathol 27: 1407-1417. doi:10.1097/00000478-200311000-00002. PubMed: 14576473.
28. Ryan P, Mulligan AM, Aronson M, Ferguson SE, Bapat B et al. (2012) Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. Cancer 118: 681-688. doi:10.1002/cncr.26323. PubMed: 21721000.
29. Hitchins MP, Ward RL (2009) Constitutional (germline) MLH1 epimutation as an aetiological mechanism for hereditary non-polyposis colorectal cancer. J Med Genet 46: 793-802.
30. Westin SN, Lacour RA, Urbauer DL, Luthra R, Bodurka DC et al. (2008) Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol 26: 5965-5971. doi: 10.1200/JCO.2008.18.6296. PubMed: 19001318.
31. Masuda K, Banno K, Hirasawa A, Yanokura M, Tsuji K et al. (2012) Relationship of lower uterine segment cancer with Lynch syndrome: a novel case with an hMLH1 germline mutation. Oncol Rep 28(5): 1537-1543. PubMed: 22940821.
32. Mills AM, Liou S, Kong CS, Longacre TA (2012) Are women with endocervical adenocarcinoma at risk for lynch syndrome? Evaluation of 101 cases including unusual subtypes and lower uterine segment tumors. Int J Gynecol Pathol 31: 463-469. doi:10.1097/PGP. 0b013e31824a1dad. PubMed: 22833088.
33. Buttin BM, Powell MA, Mutch DG, Babb SA, Huettner PC et al. (2004) Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history. Am J Hum Genet 74: 1262-1269. doi:10.1086/421332. PubMed: 15098177.
34. Hendriks YM, Wagner A, Morreau H, Menko F, Stormorken A et al. (2004) Cancer risk in hereditary nonpolyposis colon cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 1: 17-25.
35. Lynch HT, Harris RE, Lynch PM, Guirgis HA, Lynch JF, Bardawil WA (1977) Role of heredity in multiple primary cancer. Cancer 40: 1849-1854. doi:10.1002/1097-0142(197710)40:4+ PubMed: 907988
36. Mecklin JP, Järvinen HJ (1986) Clinical features of colorectal carcinoma in cancer family syndrome. Dis Colon Rectum 29: 160-164. doi:10.1007/BF02555012. PubMed: 3943429.
37. Win AK, Lindor NM, Winship I, Tucker KM, Buchanan DD et al. (2013) Risks of colorectal cancer and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst 105: 274-279. doi: 10.1093/jnci/djs525. PubMed: 23385444.
38. Lu KH, Dinh M, Kohlmann W, Watson P, Green J et al. (2005) Gynecologic cancer as a 'sentinel cancer' for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 105: 569-574. doi:10.1097/01.AOG.0000154885. 44002.ae. PubMed: 15738026.
39. Li F, Mao G, Tong D, Huang J, Gu L et al. (2013) The Histone Mark H3K36me3 Regulates Human DNA Mismatch Repair through Its Interaction with MutSá. Cell 153: 590-600. doi:10.1016/j.cell.2013.03.025. PubMed: 23622243.
40. Church DN, Briggs SE, Palles C, Domingo E, Kearsey SJ et al. (2013) DNA polymerase {varepsilon} and ä exonuclease domain mutations in endometrial cancer. Hum Mol Genet 22: 2820-2828. doi:10.1093/hmg/ddt131. PubMed: 23528559.
41. Resnick K, Straughn JM Jr, Backes F, Hampel H, Matthews KS, Cohn DE (2009) Lynch syndrome screening strategies among newly diagnosed endometrial cancer patients. Obstet Gynecol 114: 530-536. doi:10.1097/AOG.0b013e3181b11ecc. PubMed: 19701031.
42. Kwon JS, Scott JL, Gilks CB, Daniels MS, Sun CC, Lu KH (2011) Testing women with endometrial cancer to detect Lynch syndrome. J Clin Oncol 29: 2247-2252. doi:10.1200/JCO.2010.32.9979. PubMed: 21537049.
43. Shia J, Tang LH, Vakiani E, Guillem JG, Stadler ZK et al. (2009) Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol 33: 1639-1645. doi:10.1097/PAS.0b013e3181b15aa2. PubMed: 19701074.
44. Mojtahed A, Schrijver I, Ford JM, Longacre TA, Pai RK (2011) A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumours, and gynecologic tract carcinomas. Mod Pathol 24: 1004-1014. doi:10.1038/modpathol.2011.55. PubMed: 21499234.